Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-SID Panzyga prophylaxis study in chronic lymphocytic leukemia
2023-509737-39-00Phase 3Completed
- Sponsor
- Octapharma Pharmazeutika Produktionsgesellschaft mbH
- Start
- Aug 2020
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Panzyga with Placebo (2 arms). Primary endpoint: Occurrence of at least one major infection. Started Aug 2020; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-509737-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509737-39-00.